Mass General Cancer Center Announces 2024 Recipients of Krantz Awards for Cancer Research
The 2024 class of awardees will receive more than $6 million in funding to accelerate groundbreaking cancer research.
The 2024 class of awardees will receive more than $6 million in funding to accelerate groundbreaking cancer research.
The researchers found that damage to the heart is driven by a different immune response than the anti-tumor one, suggesting that this serious complication could one day be managed without halting cancer therapy.
Cesar M. Castro, MD, MSc, of the Department of Medicine and Center for Systems Biology at Massachusetts General Hospital, and Hakho Lee, PhD, of the Department of Radiology and Center for Systems Biology at Massachusetts General Hospital, are co-corresponding authors of a paper published in Nature Biotechnology, “Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE.”
The John and Ashley Ranelli Endowed Scholar in Cancer Innovation will activate funding of promising cancer research, helping to advance critical work in the fight against cancer.
Nabeel Bardeesy, PhD, an investigator in the Krantz Center for Cancer Research in the Mass General Cancer Center and a Professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Discovery, DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer Through Impaired SIK Signaling and CRTC2/p300-mediated Transcriptional Reprogramming, a collaboration with Taran Gujral at Fred Hutchinson Cancer Institute in Seattle.
Researchers demonstrated the equivalence of the effect of delivering early palliative care via video versus in-person visits on quality of life in patients with advanced lung cancer.
Newly defined strategy will extend the frontier for research-driven excellence in cancer care across all patients and across all communities.
A study led by researchers at Mass General Brigham has found that an individualized cancer therapy tailored to the unique tumor profiles of patients with melanoma and lung cancer was well-tolerated and boosted immune activity.
The findings challenge the use of pack-year smoking history in determining lung cancer screening eligibility and support the use of smoking duration cutoffs instead.
Researchers report a new pathway underlying the anti-cancer mechanism of mIDH1 inhibitors, involving the process of “viral mimicry.”
An integral part of one of the world’s most distinguished academic medical centers, Mass General Cancer Center is among the leading cancer care providers in the United States.